Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an ...

She said the company is discussing the next steps for the drug with the FDA, including how to design a phase three trial on the pill. Eli Lilly estimates that "it's probably going to be four or ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Eli Lilly is racing to get the first weight-loss pill on the market Why it's interesting ... Amgen says this makes it easier for the body to burn fat. "This is fascinating because it appears ...

Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...

On the other hand, Eli Lilly is working on the next generation of weight management treatments. The most advanced product candidates in this sector are Orforglipron (GLP-1 oral pill), and ...